US scientists develop fentanyl vaccine effective in mice

American scientists have created an experimental vaccine that shows promise in protecting against fentanyl and its synthetic derivatives, according to research published in the "Journal of Medicinal Chemistry." In studies involving mice, the vaccine successfully trained the animals' immune systems to recognize and neutralize a wide range of fentanyl-related compounds, including novel substances emerging on the illicit market.

Fentanyl and its potent analogs are a major driver of the opioid crisis in the United States, causing tens of thousands of deaths each year. The challenge for researchers has been the rapid appearance of new fentanyl variants, making it difficult for targeted vaccines to keep pace. Previous vaccine development efforts often focused on specific substances, rendering them less effective as the drug landscape evolved.

The new approach, developed by researchers at the Scripps Research Institute, aims to overcome this limitation by targeting the entire class of fentanyl compounds. They engineered a modified molecule that shares key chemical features with fentanyl but differs enough to elicit a broad immune response. When used in a vaccine, this molecule, combined with a carrier protein, prompted mice to produce antibodies capable of binding not only to fentanyl but also to several derivatives like carfentanil, acetylfentanyl, and furanylfentanyl. Importantly, these antibodies did not react with medically used opioids such as morphine or oxycodone.

Following vaccination, mice were administered fentanyl. Those that received the vaccine exhibited significantly reduced respiratory depression, a common and dangerous side effect of high fentanyl doses, compared to a control group. Further analysis indicated that approximately 70% less fentanyl reached the brains of the vaccinated mice. This suggests that the vaccine could be a viable strategy to mitigate the lethal effects of fentanyl overdoses and potentially curb the ongoing epidemic.